Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.25826676.v1

Key Points

Non-regulatory CD4+ T cell composition exhibits distinct dynamic changes following preoperative durvalumab with or without tremelimumab in head and neck squamous cell carcinoma.
Randomized clinical trial evaluation tracks cellular immune shifts across treatment arms to assess preoperative durvalumab and tremelimumab effects on resectable carcinoma tissues.
Highlights cellular immunological remodeling induced by immune checkpoint inhibition, supporting further investigation of CD4+ T cell dynamics in preoperative head and neck cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized clinical trial reveals dynamic shifts in non-regulatory CD4+ T cell composition in resectable head and neck squamous cell carcinoma, highlighting preoperative immunotherapy mechanisms.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e6a13db6db643587624d8e https://doi.org/10.1158/1078-0432.25826676.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading